Get the Stockscreener App
8.66
5.46%
-0.50
Pre-market:
9.43
0.77
+8.89%
Regenxbio Inc stock is traded at $8.66, with a volume of 648.68K.
It is down -5.46% in the last 24 hours and down -2.59% over the past month.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
See More
Previous Close:
$9.16
Open:
$9.05
24h Volume:
648.68K
Relative Volume:
0.56
Market Cap:
$494.31M
Revenue:
$89.04M
Net Income/Loss:
$-241.08M
P/E Ratio:
-1.6464
EPS:
-5.26
Net Cash Flow:
$-194.72M
1W Performance:
-11.72%
1M Performance:
-2.59%
6M Performance:
+2.24%
1Y Performance:
-25.60%
1-Day Range:
$8.62
$9.32
1-Week Range:
$8.62
$10.64
52-Week Range:
$5.035
$15.36
Regenxbio Inc Stock (RGNX) Company Profile
Name
Regenxbio Inc
Sector
Industry
Phone
240-552-8181
Address
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Compare RGNX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RGNX
Regenxbio Inc
|
8.66 | 494.31M | 89.04M | -241.08M | -194.72M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.99 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
508.86 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.71 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
540.71 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
254.09 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Regenxbio Inc Stock (RGNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-11-25 | Downgrade | Goldman | Buy → Neutral |
| Feb-07-25 | Resumed | Raymond James | Outperform |
| Nov-15-24 | Resumed | Morgan Stanley | Overweight |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Jun-07-24 | Initiated | Goldman | Buy |
| Mar-11-24 | Initiated | H.C. Wainwright | Buy |
| Mar-08-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-06-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-21-24 | Resumed | Raymond James | Outperform |
| Nov-01-23 | Initiated | Stifel | Buy |
| Jun-02-23 | Initiated | Robert W. Baird | Outperform |
| Jun-23-22 | Initiated | Berenberg | Buy |
| Dec-15-21 | Initiated | Wedbush | Neutral |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Jan-06-21 | Upgrade | Raymond James | Outperform → Strong Buy |
| Dec-16-20 | Initiated | UBS | Buy |
| Jun-25-20 | Resumed | BofA/Merrill | Buy |
| May-13-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Aug-20-19 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Jun-18-19 | Reiterated | Chardan Capital Markets | Buy |
| Jun-14-19 | Resumed | Raymond James | Outperform |
| Jun-05-19 | Reiterated | Chardan Capital Markets | Buy |
| Feb-25-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-05-19 | Upgrade | Raymond James | Outperform → Strong Buy |
| Dec-17-18 | Reiterated | Chardan Capital Markets | Buy |
| Nov-08-18 | Reiterated | BofA/Merrill | Neutral |
| Aug-08-18 | Reiterated | Chardan Capital Markets | Buy |
| Jul-23-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jul-10-18 | Reiterated | Chardan Capital Markets | Buy |
| May-09-18 | Reiterated | Barclays | Overweight |
| Apr-09-18 | Reiterated | Chardan Capital Markets | Buy |
| Mar-12-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-13-18 | Initiated | Mizuho | Neutral |
| Nov-09-17 | Resumed | Morgan Stanley | Overweight |
View All
Regenxbio Inc Stock (RGNX) Latest News
Regenxbio (RGNX) Maintains Strong Outlook Amid Competitor Safety Concerns | RGNX Stock News - GuruFocus
REGENXBIO announces royalty monetization agreement for up to $250M - MSN
REGENXBIO (RGNX) Prepares for Potential $4M Warrant Cash Influx - GuruFocus
Regenxbio (RGNX) Proposes Sale of Over 268,000 Shares | RGNX Stock News - GuruFocus
Regenxbio (RGNX) Maintains Buy Rating with $52 Price Target | RGNX Stock News - GuruFocus
A Glimpse Into The Expert Outlook On Regenxbio Through 8 Analysts - Benzinga
Promising RGX-202 Trial Results Justify Buy Rating for RegenXBio Amid Market Skepticism - TipRanks
REGENXBIO updates Phase 1/2 data for Duchenne candidate - MSN
Regenxbio's RGX-121 Could Become The New Standard Of Care In Hunter Syndrome - Seeking Alpha
H.C. WAINWRIGHT MAINTAINS BUY RATING ON REGENXBIO STOCK AFTER POSITIVE TRIAL DATA - Investing.com Nigeria
Duchenne gene therapy interim trial outcomes "striking" - marketscreener.com
Otsuka tops Vera with kidney drug data; Regenxbio sinks on Duchenne update - BioPharma Dive
RegeNXBio shares fall, despite positive new data on RGX-202 - The Pharma Letter
REGENXBIO reports progress in Duchenne treatment trial By Investing.com - Investing.com South Africa
Regenxbio’s Duchenne gene therapy data positive as shares falter - BioWorld MedTech
New Regenxbio DMD Data Support Gene Therapy Accelerated Approval - insights.citeline.com
Stifel reiterates Buy rating on Regenxbio stock after trial data By Investing.com - Investing.com Nigeria
Stifel reiterates Buy rating on Regenxbio stock after trial data - Investing.com Australia
REGENXBIO reports new positive functional data from phase I/II AFFINITY Duchenne® trial of RGX-202 - Pipelinereview
Regenxbio’s Gene Therapy Helps Kids with Deadly Muscle Disease - Bloomberg
Transcript : REGENXBIO Inc.Special Call - marketscreener.com
Regenxbio (RGNX) Reports Positive Data for RGX-202 Gene Therapy Trial - GuruFocus
Regenxbio (RGNX) Reports Promising Interim Results for Duchenne Therapy | RGNX Stock News - GuruFocus
REGENXBIO reports progress in Duchenne treatment trial - Investing.com Australia
REGENXBIO stock in focus after data for Duchenne drug (RGNX) - Seeking Alpha
Regenxbio Reports New Positive Functional Data From Phase I/Ii Affinity Duchenne® Trial Of Rgx-202 - marketscreener.com
REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II A - GuruFocus
REGENXBIO Inc. (NASDAQ:RGNX) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202 | RGNX Stock News - GuruFocus
REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202 - PR Newswire
RegenXBio Holds 2025 Annual Stockholders Meeting - TipRanks
ProShare Advisors LLC Boosts Stake in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World
Bank of America Corp DE Reduces Stock Holdings in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World
REGENXBIO to Host Webcast Discussing Interim Functional Data from the Phase I/II AFFINITY DUCHENNE® Trial of RGX-202 - Citizen Tribune
REGENXBIO to Host Webcast Discussing Interim Functional Data fro - GuruFocus
REGENXBIO to Host Webcast Discussing Interim Functional Data from the Phase I/II AFFINITY DUCHENNE® Trial of RGX-202 | RGNX Stock News - GuruFocus
Leerink Partnrs Weighs in on REGENXBIO FY2026 Earnings - Defense World
Ameriprise Financial Inc. Has $2.20 Million Stake in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $775,000 Stock Position in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World
D. E. Shaw & Co. Inc. Raises Position in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World
REGENXBIO’s SWOT analysis: gene therapy firm’s stock poised for growth By Investing.com - Investing.com UK
REGENXBIO’s SWOT analysis: gene therapy firm’s stock poised for growth - Investing.com Australia
REGENXBIO Inc. (NASDAQ:RGNX) Shares Bought by Deutsche Bank AG - Defense World
Finance Watch: Public Company Fundraising Sank Across The Board In Q1 - insights.citeline.com
REGENXBIO’s $250 Million Royalty Bond Agreement with HealthCare Royalty - Global Legal Chronicle
Coave Therapeutics Establishes New Scientific Advisory Board to Accelerate Innovation in Genetic Medicines for Eye and CNS Diseases - GlobeNewswire Inc.
Regenxbio Inc Stock (RGNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):